Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model

https://doi.org/10.1016/0960-0760(96)00018-0Get rights and content

Abstract

In most patients with prostate cancer, continuous androgen suppression (CAS) therapy causes tumour regression and an accompanying decrease in serum prostate specific antigen (PSA). However, with tumour progression, regulation of both tumour growth and PSA gene expression becomes androgen-independent. Because androgen resistance develops, in part, from adaptive cell survival mechanisms activated by androgen withdrawal, we hypothesize that intermittent re-exposure to androgens may prolong time to androgen-independent progression. The objective of this study was to determine whether intermittent androgen suppression (IAS) could delay the onset of androgen-independent PSA gene regulation in LNCaP prostate tumour model when compared to CAS. Five or six cycles of IAS were possible before progression developed. IAS prolonged time to androgen-independent PSA gene regulation from an average of 26 days in CAS to 77 days in IAS. Serum PSA increased above pre-castrate levels in all mice treated with CAS by 28 days post-castration, but remained below pre-castrate levels in 75% of IAS-treated mice by 60 days post-castration. By 15 weeks post-castration, serum PSA levels increased 7-fold above pre-castrate levels in CAS-treated mice compared to 1.9-fold increase in IAS-treated mice. PSA mRNA expression levels highly correlated with serum PSA levels in both groups. Maintenance of androgen dependency through IAS may be due to androgen-induced differentiation and/or down-regulation of androgen-suppressed gene expression.

References (32)

  • JanknegtR.A. et al.

    Orchiectomy and Anandron (Nilutamide) or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial

    J. Urol.

    (1993)
  • HsiehJ.-T. et al.

    Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline

    Cancer Res.

    (1993)
  • GleaveM. et al.

    Acceleration of human prostate cancer in vivo by factors produced by prostate and bone fibroblasts

    Cancer Res.

    (1991)
  • GleaveM. et al.

    Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors

    Cancer Res.

    (1992)
  • BruchovskyN. et al.

    Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma

    Cancer Res.

    (1990)
  • AkakuraK. et al.

    Effects of intermittent androgen suppression on androgen-dependent tumors; apoptosis and serum prostate-specific antigen

    Cancer

    (1993)
  • Cited by (189)

    View all citing articles on Scopus
    View full text